Today is 2022-01-17 Monday,Welcome to this site 

Industry information

The huge wave of mergers and acquisitions in the biopharmaceutical industry will continue

Word:[Big][Middle][Small] QR Code 2017/8/3     Viewed:    
  Mergers and acquisitions in the biopharmaceutical industry took a big step forward in 2015, a trend analysts expect to continue through 2015. Companies are racking their brains to sign deals at an alarming rate, not just between two parties, but on multiple levels.

  However, many pharmaceutical companies are still looking for deals that could make a difference. One of the pharmaceutical companies is Pfizer, whose chief executive, Ian Shapiro, runs a company called Pfizer. Ian Read has said he plans to keep his dream of inversions alive until next year.

  In 2014, it looked as if U.S. pharmaceutical companies had been scrambling to acquire overseas drugmakers, hoping to move their headquarters to tax-friendly countries. Among them is Mylan"s takeover of Abbott"s Dutch generics division. Horizon"s acquisition of Ireland"s Vidara therapeutics company; And, of course, Pfizer"s bid for AstraZeneca, a big British pharmaceutical company, to name a few.

  In the fall of 2015, the U.S. Treasury Department introduced tougher rules and regulations to restrict companies from moving headquarters, and after that, it appeared that the migration fever had cooled. One example is AbbVie, which abruptly ended its $55 billion takeover of Shire. Smaller companies such as Salix Pharmaceuticals of north Carolina have also canceled their own transatlantic m&a deals.

  So far, however, Mr Reid is still preparing to bring the idea of cross-border m&a into 2015. "I don"t think there"s any reason why we don"t have an inversion plan, with or without the Treasury"s rules and regulations, as long as there"s value," Mr. Reid said in October. What is another m&a trend that is likely to continue in the New Year? That"s the trade in health care consumer goods. Companies are hopeful about growth in this area, especially in countries with emerging markets, where there is a growing middle class of consumers.

  Some big pharma"s biggest trading is to seek an advantageous status in this field, after the merger and acquisition activity this year, these companies will likely continue to initiate m&a, in order to can came out on top in the industry. In April, GlaxoSmithKline (GlaxoSmithKline) and Novartis (Novartis) to reach an agreement, established a mainly controlled by GlaxoSmithKline health consumer products a joint venture, the two companies in a leading position in the field of global over-the-counter drugs, the impact in the industry.

  Bayer (Bayer) quickly followed suit, bought for $14.2 billion to Merck (Merck) of over-the-counter medicines, it is already Bayer this year second non-prescription drugs on the implementation of the action, had acquired before China"s yunnan hong pharmaceutical (Dihon). But it still can"t meet in order to make the German pharmaceutical company achieve its goals - in a position of the boss in the whole world, it means that we will likely see bayer will be more action. Is not only a bayer took action, and many other pharmaceutical companies have also recently in the field of non-prescription drugs is active, including like Sanofi (Sanofi) of the company and some of the smaller firms such as its high (Perrigo). Sanofi has strengthened its presence in health-care consumer goods by acquiring Chattem of Tennessee. This year, berrigo strengthened its health-care consumer products business by acquiring Belgium"s Omega Pharma for $4.5 billion.

  Of course, all eyes will be on Bill Clinton, the activist investor. Mr Ackermann (Bill Ackman), see him at the lang company this year (Valeant) acquisition battle of Allergan company (Allergan) demonstrated irregular trading tactics will be popular. Ackermann wei lang company cooperation with Canada, helping the company takeover allergan company headquarters is located in California, he then quietly overweight allergan shares, become the pharmaceutical company"s largest shareholder, he tried to use the status in the following a hostile bid for influence in the process.

  While the move may prompt acquisitive companies to think in an unnatural way, they may not necessarily choose the same way. There are two reasons. First, there is no significant explanation for the failure of the two companies in the merger battle. Actavis eventually bought eljian in a mega-deal that would put the consortium in the top 10 in the pharmaceutical industry in terms of profits and taxes. Second, the securities and exchange commission is currently investigating possible insider trading.

  But ackermann himself may not give up. Shortly before kill carlos tevez o company come in, Mr Ackermann paid $1.5 billion for the animal health industry pioneer corporation to recognize (Zoetis) of the company, a move that caused the rumors, said he tried to sells the unit of Pfizer to wei lang or another drug companies, and wei lang"s President has said there is interest in this field.

  Will ackermann try again? Or will others imitate him? Let"s wait and see.

Go Back